Regina Umarova
Overview
Explore the profile of Regina Umarova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ali R, Haddad J, Quinn G, Zhang G, Townsend E, Scheuing L, et al.
Hepatol Commun
. 2024 Jul;
8(7).
PMID: 38967598
Background: Bile acids mediate gut-liver cross-talk through bile acid receptors. Serum, hepatic, and microbial bile acid metabolism was evaluated in HCV-compensated chronic liver disease. Methods: Patients underwent liver biopsy; portal...
2.
Quinn G, Ali R, Zhang G, Hill K, Townsend E, Umarova R, et al.
Liver Int
. 2023 Sep;
43(12):2701-2712.
PMID: 37752797
Background & Aims: Direct-acting antiviral (DAA) therapy has revolutionized treatment for the hepatitis C virus (HCV). While DAA therapy is common, little is known about the intrahepatic immunological changes after...
3.
Ali R, Quinn G, Umarova R, Haddad J, Zhang G, Townsend E, et al.
Nat Microbiol
. 2022 Dec;
8(1):12-27.
PMID: 36522461
The gut and liver are connected via the portal vein, and this relationship, which includes the gut microbiome, is described as the gut-liver axis. Hepatitis C virus (HCV) can infect...
4.
Gara N, Tana M, Kattapuram M, Auh S, Sullivan L, Fryzek N, et al.
Hepatol Commun
. 2021 Sep;
5(11):1888-1900.
PMID: 34558806
Nucleoside analogue (NA) therapy for chronic hepatitis B (CHB) is associated with improved clinical outcomes, but usually requires long-term use. Whether treatment can be safely withdrawn and the factors associated...
5.
Hild B, Dreier M, Oh J, McCulloch J, Badger J, Guo J, et al.
Nat Metab
. 2021 Aug;
3(8):1042-1057.
PMID: 34417593
Obesity and its consequences are among the greatest challenges in healthcare. The gut microbiome is recognized as a key factor in the pathogenesis of obesity. Using a mouse model, we...
6.
Podszun M, Alawad A, Lingala S, Morris N, Huang W, Yang S, et al.
Redox Biol
. 2020 Sep;
37:101710.
PMID: 32920226
Oxidative stress (OS) in non-alcoholic fatty liver disease (NAFLD) promotes liver injury and inflammation. Treatment with vitamin E (α-tocopherol, αT), a lipid-soluble antioxidant, improves liver injury but also decreases steatosis,...
7.
17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury
Ma Y, Brown P, Lin D, Ma J, Feng D, Belyaeva O, et al.
Hepatology
. 2020 Aug;
73(5):1701-1716.
PMID: 32779242
Background And Aims: 17-Beta hydroxysteroid dehydrogenase 13 (HSD17B13) is genetically associated with human nonalcoholic fatty liver disease (NAFLD). Inactivating mutations in HSD17B13 protect humans from NAFLD-associated and alcohol-associated liver injury,...
8.
Cheng X, Uchida T, Xia Y, Umarova R, Liu C, Chen P, et al.
J Clin Invest
. 2020 Mar;
130(6):3205-3220.
PMID: 32163375
In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied...